Total: $185.49M |
||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Antares Pharma Inc. (MEDJ) | Private placement of common stock | 0.5S | $3 | Antares completed the final $3M of a $10M private placement; the first $7M was raised in early February (3/6) |
Atlantic Technology Ventures Inc. (ATLC) | Common stock purchase agreement | N/A | $6 | Fusion Capital Fund II LLC bought $6M of Atlantic's common stock (3/19) |
Axys Pharmaceuticals Inc. (AXPH) | Exercise of options for common stock | 2.4S | N/A | Bay City Capital acquired about 2.4M shares of Axys common stock through the exercise of options (3/19) |
CollaGenex Pharmaceuticals Inc. (CGPI) | Private placement of common stock | 1.5S (plus warrants to purchase 0.4S) | $7.5 | CollaGenex closed a $7.5M equity financing with the sale of 1.5M shares at $5 per share and warrants to purchase 400,000 shares at $6 per share (3/13) |
Helix BioPharma Corp. (Canada; TSE:HBP) | Exercise of warrants | 1.23W | C$3.93 (US$2.56) | Helix raised US$2.56M through the exercise of 1.23M Series A warrants, which resulted in the issuance of 1.23M common shares at C$3.50 per share (3/6) |
Hyseq Inc. (HYSQ) | Drawdown of credit line | N/A | $20 | Hyseq drew down $20M available under its line of credit with company chairman George Rathmann (3/21) |
IGEN International Inc. (IGEN) | Private placement of common stock | 0.79S | $9.5 | IGEN sold 789,075 shares for $9.5M to Acqua Wellington North American Equities Fund Ltd. under an equity financing agreement struck in February covering the sale of up to $60M of IGEN's stock over 28 months (3/16) |
Martek Biosciences Corp. (MATK) | Private placement of common stock | 1.28S (plus warrants to purchase 0.3S) | $20 | Martek raised $20M in the financing; J.P. Morgan H&Q acted as placement agent for the financing; the warrants have a five-year term and are exercisable immediately at $19.05 per share (3/2) |
MGI Pharma Inc. (MOGN) | Flexible underwritten equity facility | N/A | | MGI Pharma made an arrangement to sell up to $100M in stock from shelf-registration shares to Ramius Securities LLC over a two-year period (3/1) |
Nastech Pharmaceutical Co. Inc. (NSTK) | Private placement of common stock | 0.86S | $4.2 | Nastech raised about $4.2M through a private sale of 860,000 shares to investors, including Safeco Growth Opportunities Fund and an asset management division of a money center bank; Jesup & Lamont Securities Corp. acted as placement agent (3/22) |
NeoTherapeutics Inc. (NEOT) | Private placement of common stock and warrants | 1.25S and 0.125W | $5 | NeoTherapeutics raised $5M in a private placement with IAT ReInsurance Syndicate Ltd. (3/14) |
Oxford BioMedica plc (UK; LSE:OXB) | Private placement of common stock | 172.3S | #27 (US$39.53) | Oxford expected to raise US$39.53M in a private placement being underwritten by N.M. Rothschild & Sons Ltd., and Beeson Gregory Ltd. (3/12) |
Triangle Pharmaceuticals Inc. (VIRS) | Private placement of Series B preferred stock | 0.2S | $12 | Triangle raised $12M through the sale of 200,000 Series B preferred shares to an undisclosed group of investors; the $12M was added to a $46.2M private placement announced in January; Bank of America Securities LLC served as placement agent (3/12) |
V.I. Technologies (VITX) | Private placement of common stock | 1.6S | $10 | V.I. Technologies raised $10M in the equity placement with the State of Wisconsin Investment Board (3/5) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
LSE = London Stock Exchange; TSE = Toronto Stock Exchange |
||||
N/A = Not available or reported. |
||||
@ Dates refer to the date of the press release. |